高级检索
当前位置: 首页 > 详情页

Higher expression level of tyrosine kinase-like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011 [2]Department of Oncology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China
出处:
ISSN:

关键词: tyrosine kinase-like orphan receptor 2 Wnt member 5a papillary thyroid carcinoma tumor

摘要:
The tyrosine kinase-like orphan receptor 2 (ROR2) has a wnt-mediated, pro-tumorigenic role in certain types of cancer. The present study was designed to assess the protein expression level of ROR2 and its putative ligand Wnt member 5a (Wnt5a), as well as the association with clinicopathological features in papillary thyroid carcinoma (PTC). A total of 58 patients were recruited, resulting in 58 human PTC tissue samples and their paired adjacent noncancerous tissue samples being obtained. The protein expression levels of ROR2 and Wnt5a were evaluated by immunohistochemistry and western blotting, and messenger RNA expression levels were determined by reverse transcription-quantitative polymerase chain reaction. ROR2 and Wnt5a protein and mRNA expression were significantly overexpressed in PTC tissues (P<0.05). The present study also revealed that ROR2 and Wnt5a were significantly associated with tumor stage and lymph node metastasis (P<0.05). There was a positive association between ROR2 and Wnt5a expression levels (r=0.857; P=0.007). In conclusion, ROR2 and Wnt5a may act as tumor suppressor genes in the development of PTC; overexpression of ROR2 and Wnt5a in PTC may be important for tumorigenesis and tumor development.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2017]版:
Q4 ONCOLOGY
最新[2024]版:
Q3 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011 [2]Department of Oncology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China
通讯作者:
通讯机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011 [*1]Research Center, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, Hebei 050011, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42314 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号